Skip to main content
. 2022 Mar 24;55(1):123–135. doi: 10.4143/crt.2021.1561

Table 3.

Treatment patterns in operable patients

No. (%)
Operation (breast)
 Modified radical mastectomy 165 (72.1)
 Total mastectomy 43 (18.9)
 Breast conserving surgery 11 (4.8)
 Node excision 2 (0.9)
 Not done 6 (2.6)
 Not assessed 1 (0.4)
Operation (axilla)
 ALND 135 (61.1)
 SLNB 53 (24.0)
 Not done 16 (7.2)
 Not assessed 17 (7.7)
Neoadjuvant chemotherapy
 No 212 (95.9)
 Yes 9 (4.1)
  AC followed by taxane 5 (2.3)
  DA 2 (0.9)
  Others 2 (0.9)
Adjuvant chemotherapy
 Yes 108 (48.6)
  AC followed by taxane 32 (14.5)
  AC or EC 30 (13.6)
  CMF 14 (6.3)
  FAC or FEC 13 (5.9)
  TAC 4 (1.8)
  AC followed by taxane with trastuzumab 3 (1.4)
  TC 2 (0.9)
  AC followed by trastuzumab 1 (0.5)
  Others 7 (3.2)
  Not assessed 2 (0.9)
 Completion of chemotherapy
  Yes 86 (38.9)
  No 15 (6.8)
  Not assessed 6 (2.7)
 No 107 (48.2)
 Not assessed 6 (3.2)
Adjuvant endocrine treatment
 Yes 166 (83.0)
  Tamoxifen 150 (75.0)
  Toremifen 9 (4.5)
  Aromatase inhibitor 2 (1.0)
  Others 5 (2.5)
 Total duration of treatment, median (range, mo) 48.5 (1.0–87)
 Completion of treatment
  Yes 68 (34.0)
  No 63 (31.5)
  Ongoing 23 (11.5)
  Not assessed 12 (6.0)
 No 25 (12.5)
 Not assessed 9 (4.5)
Adjuvant radiation treatment
 No 157 (71.9)
 Yes 52 (24.0)
 Not assessed 9 (4.1)

AC, adriamycin-cyclophosphamide; ALND, axillary lymph node dissection; CMF, cyclophosphamide-methotrexate-5-fluorouracil; DA, docetaxel-adriamycin; EC, epirubicin-cyclophosphamide; FAC, 5-fluorouracil-adriamycin-cyclophosphamide; FEC, 5-fluorouracil-epirubicin-cyclophosphamide; SLNB, sentinel lymph node biopsy; TAC, docetaxel-adriamycin-cyclophosphamide; TC, docetaxel-cyclophosphamide.